Fiszer-Maliszewska L, Mordarski M, Madej J A
Department of Microbiology, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław.
Arch Immunol Ther Exp (Warsz). 1993;41(1):1-9.
Several transplantable lines were derived from spontaneous tumors of mouse strains of low and high cancer incidence (CBA, BALB/c and DBA/2), and eight of them were used for an evaluation of the therapeutic potential of BRM. The lowest number of cells inducing tumors was in most cases around 10(4) cells. In transplantation tests, tumors of CBA and DBA/2 mice were non-immunogenic, while tumors of BALB/c mice showed different level of immunogenicity. Transplantation of a small number of tumor cells in admixture with BCG resulted in no tumor growth of the immunogenic line X6 and no effect on take rate of non-immunogenic line X1. Sensitivity of studied tumor lines to BCNU, CY and ADR was moderate. Therapy of the tumors with postulan and CMA, two biomodulators already shown to be active against various experimental tumors, failed. The significant therapeutic response was observed in DBA/2 mice bearing i.p. transplant of lymphosarcoma X19 and treated with i.p. injections of CMA.
几个可移植系源自癌症发病率低和高的小鼠品系(CBA、BALB/c和DBA/2)的自发肿瘤,其中八个用于评估生物反应调节剂(BRM)的治疗潜力。在大多数情况下,诱导肿瘤的细胞数量最少约为10⁴个细胞。在移植试验中,CBA和DBA/2小鼠的肿瘤无免疫原性,而BALB/c小鼠的肿瘤表现出不同程度的免疫原性。将少量肿瘤细胞与卡介苗混合移植,导致免疫原性系X6无肿瘤生长,对非免疫原性系X1的接种率无影响。所研究的肿瘤系对卡氮芥(BCNU)、环磷酰胺(CY)和阿霉素(ADR)的敏感性中等。用已证明对各种实验性肿瘤有活性的两种生物调节剂,即波舒拉明(postulan)和胞壁酰二肽(CMA)治疗肿瘤均失败。在腹腔移植淋巴肉瘤X19并用腹腔注射CMA治疗的DBA/2小鼠中观察到了显著的治疗反应。